medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 5

<< Back Next >>

Med Int Mex 2023; 39 (5)

Cardiorrenal syndrome: What is its clinical significance?

Hinestroza LS, Camelo PG, Ruiz HGF

Language: Spanish
References: 31
Page: 768-773
PDF size: 212.60 Kb.


ABSTRACT

Cardiorenal syndrome is a bidirectional pathophysiological alteration with renal or cardiac dysfunction. Its classification and diagnosis are determined by the primary organ and the chronicity of the disease. In the treatment it is important to determine the hemodynamic state and intravascular volume allowing to establish early measures. The objective of this paper is to perform a detailed description of cardiorrenal syndrome allowing understand the importance of timely diagnosis, management, prognosis and evolution. The importance of knowing this disease is the progressive increase in patients with decompensated heart failure who are admitted to the hospital network. A literature search was performed in the PubMed and Scielo databases for updated articles in English or Spanish registered in the last five years on cardiorenal syndrome, its status, diagnosis, therapies and surveillance. Five different types of cardiorenal syndrome have been described according to the organ initially affected and its evolution. In more than 50% of patients hospitalized for decompensated heart failure some degree of renal dysfunction is found. Cardiorenal syndrome is a multifactorial disease with renal, cardiac or bilateral involvement. Follow-up laboratory test (troponins, natriuretic peptides, creatinine) determine the prognosis of each patient.


REFERENCES

  1. Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: Anoverview. Adv Chronic Kidney Dis 2018; 25 (5): 382-390.doi: 10.1053/j.ackd.2018.08.004.

  2. Zannad F, Rossignol P. Cardiorenal syndrome revisited.Circulation 2018; 138 (9): 929-944. doi: 10.1161/CIRCULATIONAHA.117.028814.

  3. Kousa O, Mullane R, Aboeata A. Cardiorenal syndrome.2021. In: StatPearls Treasure Island (FL): StatPearls Publishing;2021.

  4. Tabucanon T, Tang WHW. Right heart failure and cardiorenalsyndrome. Cardiol Clin 2020; 38 (2): 185-202. doi:10.1016/j.ccl.2020.01.004.

  5. Thind GS, Loehrke M, Wilt JL. Acute cardiorenal syndrome:Mechanisms and clinical implications. Cleve Clin J Med2018; 85 (3): 231-239. doi: 10.3949/ccjm.85a.17019.

  6. Kumar U, Wettersten N, Garimella PS. Cardiorenal syndrome:Pathophysiology. Cardiol Clin 2019; 37 (3): 251-265.doi: 10.1016/j.ccl.2019.04.001.

  7. Salleck D, John S. Das kardiorenale Syndrom [Cardiorenalsyndrome]. Med Klin Intensivmed Notfmed 2019; 114(5): 439-443. German. doi: 10.1007/s00063-017-0346-1.

  8. Alprecht-Quiroz P, Zúñiga-Pineda B, Lara-Terán JJ,Cáceres-Vinueza SV, Duarte-Vera YC. Síndrome cardiorrenal:aspectos clínicos y ecocardiográficos [Cardiorenalsyndrome: Clinical and echocardiographic aspects]. ArchCardiol Mex 2020; 90 (4): 503-510. Spanish. doi: 10.24875/ACM.20000087.

  9. Di Lullo L, Reeves PB, Bellasi A, Ronco C. Cardiorenal syndromein acute kidney injury. Semin Nephrol 2019; 39 (1):31-40. doi: 10.1016/j.semnephrol.2018.10.003.

  10. Yogasundaram H, Chappell MC, Braam B, Oudit GY.Cardiorenal syndrome and heart failure-challenges andopportunities. Can J Cardiol 2019; 35 (9): 1208-1219. doi:10.1016/j.cjca.2019.04.002.

  11. Costanzo MR. The Cardiorenal syndrome in heart failure.Heart Fail Clin 2020; 16 (1): 81-97. doi: 10.1016/j.hfc.2019.08.010.

  12. Petra E, Zoidakis J, Vlahou A. Protein biomarkers for cardiorenalsyndrome. Expert Rev Proteomics 2019; 16 (4):325-336. doi: 10.1080/14789450.2019.1592682.

  13. Uduman J. Epidemiology of cardiorenal syndrome. AdvChronic Kidney Dis 2018; 25 (5): 391-399. doi: 10.1053/j.ackd.2018.08.009.

  14. Seliger S. The cardiorenal syndrome: Mechanistic insightsand prognostication with soluble biomarkers. Curr CardiolRep 2020; 22 (10): 114. doi: 10.1007/s11886-020-01360-8.

  15. Funahashi Y, Chowdhury S, Eiwaz MB, Hutchens MP.Acute cardiorenal syndrome: models and heart-kidneyconnectors. Nephron 2020; 144 (12): 629-633. doi:10.1159/000509353.

  16. Jentzer JC, Bihorac A, Brusca SB, Del Rio-Pertuz G, KashaniK, Kazory A, et al. Contemporary management of severeacute kidney injury and refractory cardiorenal syndrome:JACC Council Perspectives. J Am Coll Cardiol 2020; 76 (9):1084-1101. doi: 10.1016/j.jacc.2020.06.070.

  17. Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, VarianK. An update on the pathophysiology and treatmentof cardiorenal syndrome. Cardiol Res 2020; 11 (2): 76-88.doi: 10.14740/cr955.

  18. Kotecha A, Vallabhajosyula S, Coville HH, Kashani K.Cardiorenal syndrome in sepsis: A narrative review. J CritCare 2018; 43: 122-127. doi: 10.1016/j.jcrc.2017.08.044.

  19. Pereira J, Boada L, Niño D, Caballero M, et al. Síndromecardiorrenal. Rev Colomb Cardiol 2017; 24 (6): 602-613.

  20. Kumar U, Wettersten N, Garimella PS. Síndrome cardiorrenal:fisiopatología. Cardiol Clin 2019; 37 (3): 251-265.doi:10.1016/j.ccl.2019.04.001

  21. Malbrain ML, Cheatham ML, Kirkpatrick A, Sugrue M, etal. Results from the international conference of expertson intra-abdominal hypertension and abdominal compartmentsyndrome. I. Definitions. Intensive Care Medicine2006; 32 (11): 1722-1732. 10.1007/s00134-006-0349-5.

  22. Bradley SE, Bradley GP. The effect of increased intraabdominalpressure on renal function in man 1. J Clin Invest1947; 26 (5): 1010-1022. doi:10.1172/JCI101867.

  23. Dalfino L, Tullo L, Donadio I, Malcangi V, Brienza N. Intraabdominalhypertension and acute renal failure in criticallyill patients. Intensive Care Medicine 2008; 34 (4): 707-713.doi: 10.1007/s00134-007-0969-4.

  24. Hostetter TH, Pfeffer JM, Pfeffer MA, Dworkin LD, BraunwaldE, Brenner BM. Cardiorenal hemodynamics andsodium excretion in rats with myocardial infarction. Am JPhysiol Heart Circulatory Physiol 1983; 245 (1): H98-H103.doi:10.1152/ajpheart.1983.245.1.H98.

  25. Johnson MD, Malvin RL. Stimulation of renal sodium reabsorptionby angiotensin II. Am J Physiol 1977; 232 (4):F298-306. doi:10.1152/ajprenal.1977.232.4.F298.

  26. Neuhofer W, Pittrow D. Role of endothelin and endothelinreceptor antagonists in renal disease. Eur J Clin Invest2006; 36 (s3): 78-88. doi:10.1111/j.1365-2362.2006.01689.

  27. Gray MO, Long CS, Kalinyak JE, Li H-T, Karliner JS. AngiotensinII stimulates cardiac myocyte hypertrophy via paracrinerelease of TGF-β1 and endothelin-1 from fibroblasts. CardiovascularResearch 1998; 40 (2): 352-363. doi: 10.1016/s0008-6363(98)00121-7.

  28. Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II andoxidative stress. Current Opin Cardiol 2007; 22 (4): 311-315.doi: 10.1097/HCO.0b013e3281532b53.

  29. Radeke HH, Meier B, Topley N, Flöge J, Habermehl GG,Resch K. Interleukin 1-alpha and tumor necrosis factoralphainduce oxygen radical production in mesangial cells.Kidney Int 1990; 37 (2): 767-775. doi: 10.1038/ki.1990.44.

  30. Tsutamoto T, Hisanaga T, Wada A, Maeda K, et al. Interleukin-6 spillover in the peripheral circulation increases withthe severity of heart failure, and the high plasma level ofinterleukin-6 is an important prognostic predictor in patientswith congestive heart failure. J Am Coll Cardiol 1998;

  31. 31 (2): 391-398. doi:10.1016/S0735-1097(97)00494-4.31. Wettersten N, Maisel AS. Biomarkers for heart failure: anupdate for practitioners of internal medicine. Am J Med2016; 129 (6): 560-567. doi:10.1016/j.amjmed.2016.01.013.




2020     |     www.medigraphic.com